|1.||Löscher, Wolfgang: 2 articles (01/2014 - 11/2013)|
|2.||Rundfeldt, Chris: 1 article (01/2014)|
|3.||Potschka, Heidrun: 1 article (11/2013)|
|4.||Twele, Friederike: 1 article (11/2013)|
|5.||Töllner, Kathrin: 1 article (11/2013)|
|6.||Hoffmann, Katrin: 1 article (11/2013)|
|7.||Freyer, Dorette: 1 article (06/2007)|
|8.||Lam, Tim T: 1 article (06/2007)|
|9.||Victorov, Ilya V: 1 article (06/2007)|
|10.||Thein, Elisabeth: 1 article (06/2007)|
03/01/2000 - "Some PIs 1 and abecarnil showed anticonvulsant properties against seizures induced by PTZ with a potency lower than that observed in audiogenic seizures. "
03/01/1993 - "Mice withdrawn from chronic administration of abecarnil (6 mg/kg/day for 12 days) showed no anxiety and no changes in seizure susceptibility and muscle tone. "
09/24/1991 - "The data indicate that, because of the response contingency in abecarnil tolerance, development of tolerance to anticonvulsant effects of this compound depends critically on seizure frequency during drug administration, while adverse effects of this compound are reduced independently of seizure frequency."
09/24/1991 - "When the same treatment protocol was used, but seizures were initiated only at the start and end of the treatment period, almost no tolerance to the anticonvulsant effect of abecarnil was measured, indicating an important role of learning processes for the development of tolerance. "
09/24/1991 - "When kindled seizures were repeatedly initiated during chronic treatment of rats with abecarnil (5 mg/kg i.p. "
|2.||Anxiety Disorders (Anxiety Disorder)
01/01/1998 - "Overall 451 patients with generalised anxiety disorder were randomised to abecarnil, 461 to placebo and 464 to active controls. "
01/01/1998 - "Abecarnil, a new beta-carboline, in the treatment of anxiety disorders."
02/01/1995 - "Abecarnil, a novel beta-carboline, is under development for the treatment of Generalized Anxiety Disorder. "
06/01/2007 - "The purpose of this study was to investigate whether the beta-carboline, abecarnil (Abe), which has already passed clinical phase III trials in patients with anxiety disorders, is neuroprotective in in vitro models of cerebral ischemia or excitotoxicity. "
01/01/1997 - "A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. "
|3.||Reflex Epilepsy (Photosensitive Epilepsy)
|4.||Myoclonus (Nocturnal Myoclonus)
|5.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
01/01/1997 - "Withdrawal symptoms emerged in patients who abruptly discontinued abecarnil (particularly at the higher dosage) only in those receiving a longer duration of treatment. "
01/01/1991 - "However, in the 3-9 mg/day abecarnil group, there were few withdrawal symptoms and almost no loss of efficacy following discontinuation."
05/01/1997 - "In this study, 49 alcohol-dependent inpatients who exhibited at least moderate symptoms of uncomplicated alcohol withdrawal were treated over a 5-day detoxification period with abecarnil or diazepam and rated daily for alcohol withdrawal symptoms and adverse events. "
05/01/1997 - "Both the abecarnil and diazepam treatment groups exhibited a similar marked reduction in withdrawal symptoms over time. "
|6.||GABA-A Receptors (GABA(A) Receptor)